SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.

Enhancing Metabolic Research Capabilities

Metabolism plays a central role in cellular functions, powering energy production and processes like biosynthesis, mitochondrial function, and cell fate decisions. Disruptions in metabolism are linked to numerous diseases, making metabolic analysis a critical area of research. Traditionally, 2D models have been used for this purpose, but they often fail to reflect the complex biological interactions that occur in living organisms.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) has announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has achieved European IVDR certification. This certification positions the assay as a Companion Diagnostic (CDx) to identify gastric or gastroesophageal junction (GEJ) adenocarcinoma patients eligible for treatment with KEYTRUDA® (pembrolizumab), a leading anti-PD-1 therapy developed by Merck. The certification expands the test’s application, offering a significant advancement in cancer treatment options for a growing patient demographic.

SHERIDAN, WYOMING – May 8, 2025 – PerkinElmer, a global leader in analytical instrumentation, is set to showcase two groundbreaking laboratory solutions at Pittcon 2025: the QSight® 500 LC/MS/MS System for high-throughput contaminant analysis and the Spotlight™ Aurora FTIR Microscope for faster material characterization. These innovative systems are designed to boost productivity, enhance accuracy, and improve operational efficiency while helping laboratories meet rigorous regulatory demands and reduce costs.

Advanced Contaminant Detection with QSight® 500 LC/MS/MS System

PerkinElmer’s QSight® 500 LC/MS/MS System is engineered to handle even the most complex sample matrices with exceptional reliability and cost efficiency. The system offers the following advantages:

SHERIDAN, WYOMING – May 8, 2025 – PerkinElmer, a global leader in analytical solutions and specialized services for the bio-pharma, applied, and food markets, has announced its acquisition of Project Farma, a subsidiary of Precision for Medicine. The acquisition, which aims to enhance PerkinElmer's OneSource professional services business, strengthens its position as a critical partner for life sciences organizations looking to accelerate the delivery of innovative therapies.

Strategic Expansion to Support Life Sciences Innovation

The acquisition of Project Farma, a renowned life sciences consultancy, marks a significant milestone in PerkinElmer’s mission to empower customers throughout the value chain. The acquisition broadens OneSource’s lab solutions offering by integrating Project Farma’s extensive experience in advancing technical operations, from initial ideation through to commercialization.

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its financial results for the first quarter of 2025. Despite navigating a challenging macroeconomic landscape, the company demonstrated solid operational performance, underscoring its commitment to driving growth and margin expansion amidst market volatility.

Financial Performance Overview

For the first quarter of 2025, Bio-Rad reported total net sales of $585.4 million, reflecting a 4.2% decrease from the $610.8 million recorded in Q1 2024. On a currency-neutral basis, the decrease was moderated to 1.5%. This decline was primarily attributed to softer sales in the Life Science segment, compounded by a decrease in academic research funding, particularly in the Americas.

Key Financial Highlights:

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a recognized leader in life science research and clinical diagnostics products, is set to announce its first-quarter financial results for 2025 on Thursday, May 1, 2025. The company will release its earnings after market close, followed by a detailed conference call to discuss the results.

Key Highlights of the Upcoming Report

Bio-Rad, headquartered in Hercules, California, is poised to share insights into its financial performance, reflecting ongoing growth and market leadership in the life sciences sector. The company’s diverse product portfolio spans across research and clinical diagnostics, with an emphasis on innovation and customer success.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has announced a notification under Article 19 of Regulation (EU) No. 596/2014 regarding share transactions carried out by individuals in managerial roles at the company. The transaction was made by Søren Jelert, the company’s Chief Financial Officer (CFO), as part of his regular financial management activities. This report includes details on the purchase of GN Store Nord shares, shedding light on the executive’s commitment to the company and the ongoing market activity surrounding its stock.

Transaction Details

On May 2, 2025, Søren Jelert made a purchase of GN Store Nord shares through Nasdaq Copenhagen. A total of 8,200 shares were acquired in two separate transactions. The shares were purchased at an average price of DKK 90.05 per share, with individual transactions priced at DKK 90.14 and DKK 89.95 for volumes of 4,200 and 4,000 shares, respectively.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has reported its Q1 2025 financial results, highlighting a mix of challenges and opportunities. The company's growth was impacted by market uncertainties, including global macroeconomic pressures and changes in consumer sentiment, particularly in the U.S. Despite these hurdles, GN has initiated proactive cost mitigation strategies aimed at ensuring long-term profitability and supporting margin growth.

Hearing Division Performance: Launch Success Amid Market Challenges

GN's Hearing division experienced a slight decline in organic revenue growth of -1%. While the strong initial uptake of the ReSound Vivia was encouraging, the division faced challenges in the U.S. market and a slowdown in sales from existing products as customers awaited the new launch. Despite these challenges, the positive reception of ReSound Vivia continued into April, positioning the company for expected market share gains.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has announced a series of strategic measures to mitigate the adverse effects of increased tariff levels, recently imposed by the U.S. administration. These proactive actions are designed to protect the company’s EBITA margin for 2025 and secure long-term earnings growth despite the heightened uncertainty in the global trade environment.

As the U.S. tariff rates continue to fluctuate, GN is positioning itself to maintain stability in its financials and minimize disruption to its operations. The company has updated its financial guidance for 2025, outlining the expected impact of tariffs, and is taking decisive steps to adjust its manufacturing strategies, product pricing, and cost management to ensure resilience.